<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40192136</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Controlling Oligopolyposis With Colonoscopy: A Cohort Study.</ArticleTitle><Pagination><StartPage>907</StartPage><EndPage>912</EndPage><MedlinePgn>907-912</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003763</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Oligopolyposis is defined as between 10 and 100 polyps in the large intestine. If the polyps are adenomas, at least 15% of affected patients will have a syndrome of hereditary colorectal cancer predisposition. Management is aimed at preventing the development of cancer, and options include chemoprevention, colectomy, and colonoscopy, with colectomy generally favored. The role of colonoscopy is relatively unexplored.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To present the results of colonoscopic control of patients with oligopolyposis.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective study of a cohort of patients with oligopolyposis separated by genotype and histology.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Hereditary colorectal cancer center.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Those with oligopolyposis preferring management with sequential colonoscopy to colectomy and who underwent at least 3 years of follow-up were included.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Colonoscopy, polypectomy, and surgical resection.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Number of colonoscopies, complications of colonoscopies, length of follow-up, number of polyps at first and last colonoscopy, size of the largest polyp at first and last colonoscopy, incidence and stage of cancer, and timing of the cancer diagnosis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 59 patients: 29 with sessile serrated polyposis, 13 with MUTYH -associated polyposis, 8 with attenuated familial adenomatous polyposis, and 9 with oligopolyposis not otherwise specified. Patients with familial adenomatous polyposis were 20 years younger than those in the other groups. Patients averaged 1 colonoscopy per year for a mean follow-up between 5 and 11 years. One patient had a post-polypectomy hemorrhage, but there was no perforation and no admission. No patient needed surgery to control benign polyposis. Nine patients had cancer, 6 diagnosed and resected before the start of the colonoscopic surveillance. Three patients with sessile serrated polyposis developed interval cancers while on surveillance, all stage 1. These 3 patients were the only ones who needed colectomy.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Relatively low numbers of familial adenomatous polyposis and oligopolyposis patients. Lack of specific data on variants.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In compliant patients and experienced hands, endoscopic control of oligopolyposis can be safe and effective. See Video Abstract .</AbstractText><AbstractText Label="CONTROLANDO LA OLIGOPOLIPOSIS MEDIANTE COLONOSCOPIA UN ESTUDIO DE COHORTE" NlmCategory="UNASSIGNED">ANTECEDENTES:La oligopoliposis se define como la presencia de entre 10 y 100 p&#xf3;lipos en el intestino grueso. En el caso que se trataran de adenomas, al menos el 15% de los pacientes afectados presentar&#xe1; una predisposici&#xf3;n al s&#xed;ndrome hereditario de c&#xe1;ncer colorrectal. El tratamiento se centra en prevenir el desarrollo del c&#xe1;ncer y las opciones incluyen quimioprevenci&#xf3;n, colectom&#xed;a y colonoscopia, siendo la colectom&#xed;a la que generalmente se prefiere. El papel de la colonoscopia es relativamente inexplorado.OBJETIVO:Presentar los resultados del control colonosc&#xf3;pico de pacientes con oligopoliposis.DISE&#xd1;O:Estudio retrospectivo de una cohorte de pacientes con oligopoliposis, separados por genotipo e histolog&#xed;a.ESCENARIO:Centro de c&#xe1;ncer colorrectal hereditario.PACIENTES:Pacientes con oligopoliposis que prefirieron el tratamiento con colonoscopia secuencial a la colectom&#xed;a, y que se sometieron a al menos tres a&#xf1;os de seguimiento.INTERVENCIONES:Colonoscopia y polipectom&#xed;a, resecci&#xf3;n quir&#xfa;rgica.PRINCIPALES MEDIDAS DE RESULTADOS:N&#xfa;mero de colonoscopias, complicaciones de las colonoscopias, duraci&#xf3;n del seguimiento, n&#xfa;mero de p&#xf3;lipos en la primera y &#xfa;ltima colonoscopia, tama&#xf1;o del p&#xf3;lipo m&#xe1;s grande en la primera y &#xfa;ltima colonoscopia, incidencia y estadio del c&#xe1;ncer, y momento del diagn&#xf3;stico.RESULTADOS:Se incluyeron 59 pacientes: 29 con poliposis serrada s&#xe9;sil, 13 con poliposis asociada a MUTYH, 8 con poliposis adenomatosa familiar (PAF) atenuada y 9 con oligopoliposis no especificada. Los pacientes con PAF eran 20 a&#xf1;os m&#xe1;s j&#xf3;venes que los dem&#xe1;s grupos. Los pacientes promediaron una colonoscopia al a&#xf1;o durante una media de seguimiento de entre 5 y 11 a&#xf1;os. Un paciente sufri&#xf3; una hemorragia pospolipectom&#xed;a, pero no se produjo ninguna perforaci&#xf3;n ni ingreso hospitalario. Ning&#xfa;n paciente requiri&#xf3; cirug&#xed;a para controlar la poliposis benigna. Nueve pacientes presentaron c&#xe1;ncer, 6 de ellos diagnosticados y resecados antes del inicio de la vigilancia colonosc&#xf3;pica. Tres pacientes con poliposis serrada s&#xe9;sil desarrollaron c&#xe1;nceres de intervalo durante la vigilancia, todos en estadio 1. Estos fueron los &#xfa;nicos pacientes que necesitaron colectom&#xed;a.LIMITACIONES:N&#xfa;mero relativamente bajo de pacientes con PAF y oligopoliposis. Falta de datos espec&#xed;ficos sobre variantes.CONCLUSIONES:En pacientes cumplidores y con experiencia, el control endosc&#xf3;pico de la oligopoliposis puede ser seguro y eficaz. (Traducci&#xf3;n-Dr Osvaldo Gauto ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Church</LastName><ForeName>James</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3489-4140</Identifier><AffiliationInfo><Affiliation>Global Center for Integrated Colorectal Surgery and IBD Interventional Endoscopy, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003113" MajorTopicYN="Y">Colonoscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003111" MajorTopicYN="Y">Colonic Polyps</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="N">Colectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011125" MajorTopicYN="Y">Adenomatous Polyposis Coli</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000236" MajorTopicYN="Y">Adenoma</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Colonoscopy</Keyword><Keyword MajorTopicYN="N">Familial adenomatous polyposis</Keyword><Keyword MajorTopicYN="N">MUTYH-associated polyposis</Keyword><Keyword MajorTopicYN="N">Oligopolyposis</Keyword><Keyword MajorTopicYN="N">Serrated polyposis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>12</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>7</Day><Hour>13</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>7</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40192136</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003763</ArticleId><ArticleId IdType="pii">00003453-202507000-00017</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Grover S, Kastrinos F, Steyerberg EW, et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA. 2012;308:485&#x2013;492.</Citation></Reference><Reference><Citation>Valle L, Monahan KJ. Genetic predisposition to gastrointestinal polyposis: syndromes, tumour features, genetic testing, and clinical management. Lancet Gastroenterol Hepatol. 2024;9:68&#x2013;82.</Citation></Reference><Reference><Citation>Dekker E, Bleijenberg A, Balaguer F; Dutch-Spanish-British Serrated Polyposis Syndrome collaboration. Update on the World Health Organization criteria for diagnosis of serrated polyposis syndrome. Gastroenterology. 2020;158:1520&#x2013;1523.</Citation></Reference><Reference><Citation>Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW; American College of Gastroenterology. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223&#x2013;262; quiz 263.</Citation></Reference><Reference><Citation>Ishikawa H, Mutoh M, Iwama T, et al. Endoscopic management of familial adenomatous polyposis in patients refusing colectomy. Endoscopy. 2016;48:51&#x2013;55.</Citation></Reference><Reference><Citation>Murano T, Ikematsu H, Shinmura K, et al. Endoscopic management of familial adenomatous polyposis targeting colorectal lesions greater than 5&#x2009;mm in size: a single-center retrospective study. Fam Cancer. 2023;22:83&#x2013;89.</Citation></Reference><Reference><Citation>Valent&#xed;n F, Guarinos C, Ju&#xe1;rez M, et al. Endoscopic surveillance in patients with multiple (10-100) colorectal polyps. Endoscopy. 2016;48:56&#x2013;61.</Citation></Reference><Reference><Citation>Abbass MA, Leach B, Church JM. The second allele: a key to understanding the timing of sporadic and hereditary colorectal tumorigenesis. Genes. 2021;12:1515.</Citation></Reference><Reference><Citation>Liang J, Kalady MF, Church J. Snaring large, serrated polyps. Surg Endosc. 2013;27:1622&#x2013;1627.</Citation></Reference><Reference><Citation>Knudsen AL, Bisgaard ML, B&#xfc;low S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer. 2003;2:43&#x2013;55.</Citation></Reference><Reference><Citation>Kaz AM, Dominitz JA. Can individuals with colonic polyposis be managed safely with colonoscopic surveillance? Endoscopy. 2016;48:7&#x2013;8.</Citation></Reference><Reference><Citation>Church J, Erkan A. Scope or scalpel? A matched study of the treatment of large colorectal polyps. ANZ J Surg. 2018;88:177&#x2013;181.</Citation></Reference><Reference><Citation>Urso EDL, Celotto F, Giandomenico F, et al. Analysis of morbidity and mortality, quality of life and bowel function after total colectomy with ileorectal anastomosis versus right and left hemicolectomy: a study to optimise the treatment of Lynch syndrome and attenuated polyposis coli. Eur J Surg Oncol. 2020;46:1613&#x2013;1619.</Citation></Reference><Reference><Citation>Duclos J, Lefevre JH, Lefran&#xe7;ois M, et al. Immediate outcome, long-term function and quality of life after extended colectomy with ileorectal or ileosigmoid anastomosis. Colorectal Dis. 2014;16:O288&#x2013;O296.</Citation></Reference><Reference><Citation>Church J. Being a colonoscopist. Dis Colon Rectum. 2023;66:1294&#x2013;1296.</Citation></Reference><Reference><Citation>Heald B, Hampel H, Church J, et al.; Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. Collaborative Group of the Americas on Inherited Gastrointestinal Cancer position statement on multigene panel testing for patients with colorectal cancer and/or polyposis. Fam Cancer. 2020;19:223&#x2013;239.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40085057</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Persistent Sitting and Walking Difficulties After Abdominoperineal Excision and Anterior Resection: Results From the Quality of Life in Rectal Cancer Study.</ArticleTitle><Pagination><StartPage>704</StartPage><EndPage>712</EndPage><MedlinePgn>704-712</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003710</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The main surgical resection options in rectal cancer are anterior resection for tumors in the mid- or upper rectum and abdominoperineal excision for tumors in the lower rectum. A previous study showed long-term persistent perineal symptoms and sitting difficulties after abdominoperineal excision.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the prevalence and extent of sitting and walking difficulties after abdominoperineal excision compared with anterior resection.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">An observational, prospective, longitudinal, multicenter, international study.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Data were collected from participants in the quality of life in rectal cancer study. Participants answered questionnaires about bodily functions, symptoms, and quality of life at baseline and at 1 and 2 years after diagnosis.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients with newly diagnosed rectal cancer, regardless of stage, were included. The study included 1024 patients, of whom 64% underwent anterior resection and 36% underwent abdominoperineal excision.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The primary objective was to estimate the prevalence and ORs of sitting or walking difficulties between the 2 surgical procedure groups: abdominoperineal excision and anterior resection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the group of patients who underwent abdominoperineal excision, 29% had sitting difficulties after 2 years compared with 12% in the group who underwent anterior resection (OR, 2.65; 95% CI, 1.71-4.09; p &lt; 0.0001). Walking difficulties after 2 years were reported by 35% after abdominoperineal excision compared with 24% after anterior resection (OR, 1.50; 95% CI, 1.02-2.22; p = 0.04).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The observational nature of the study could be regarded as a limitation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Abdominoperineal excision was associated with both sitting and walking difficulties among patients with rectal cancer at significantly higher rates compared with anterior resection. It is probable that attention from health care could improve the situation of the patients through enhanced rehabilitation. See Video Abstract .</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov (NCT01477229).</AbstractText><AbstractText Label="DIFICULTADES PERSISTENTES PARA SENTARSE Y CAMINAR POSTERIOR A LA ESCISIN ABDOMINOPERINEAL Y RESECCIN ANTERIOR RESULTADOS DEL ESTUDIO QOLIRECT" NlmCategory="UNASSIGNED">ANTECEDENTES:Las principales opciones de resecci&#xf3;n quir&#xfa;rgica en el c&#xe1;ncer de recto son la resecci&#xf3;n anterior para los tumores en el recto medio o superior y la escisi&#xf3;n abdominoperineal para los tumores en el recto inferior. Un estudio previo mostr&#xf3; s&#xed;ntomas perineales persistentes a largo plazo y dificultades para la sedestaci&#xf3;n posterior a la escisi&#xf3;n abdominoperineal.OBJETIVO:Examinar la prevalencia y el grado de dificultades para sentarse y caminar despu&#xe9;s de la escisi&#xf3;n abdominoperineal en comparaci&#xf3;n con la resecci&#xf3;n anterior.DISE&#xd1;O:Estudio observacional, prospectivo, longitudinal, multic&#xe9;ntrico e internacional.ESTABLECIMIENTOS:Se recopilaron datos de los participantes en el estudio QoLiRect. Los participantes respondieron cuestionarios sobre funciones corporales, s&#xed;ntomas y calidad de vida al inicio y tras 1 y 2 a&#xf1;os posterior al diagn&#xf3;stico.PACIENTES:Se incluyeron pacientes con c&#xe1;ncer de recto de reciente diagn&#xf3;stico independientemente del estadio. El estudio incluy&#xf3; a 1024 pacientes, de los cuales el 64 % fueron sometidos a una resecci&#xf3;n anterior y el 36 % a una escisi&#xf3;n abdominoperineal.PRINCIPALES MEDIDAS DE RESULTADOS:El objetivo principal fue estimar la prevalencia y los odds ratios (OR) de dificultades para sentarse o caminar entre los dos grupos de procedimientos quir&#xfa;rgicos: escisi&#xf3;n abdominoperineal y resecci&#xf3;n anterior.RESULTADOS:En el grupo de pacientes sometidos a la escisi&#xf3;n abdominoperineal, el 29% ten&#xed;a dificultades para sentarse tras 2 a&#xf1;os posterior a la cirug&#xed;a en comparaci&#xf3;n con el 12% en el grupo que fue sometido a resecci&#xf3;n anterior (OR 2,65, IC del 95% 1,71-4,09, p &lt; 0,0001). Las dificultades para caminar posterior a los 2 a&#xf1;os se informaron en el 35% despu&#xe9;s de la escisi&#xf3;n abdominoperineal en comparaci&#xf3;n con el 24% despu&#xe9;s de la resecci&#xf3;n anterior (OR 1,50, IC del 95% 1,02-2,22, p = 0,04).LIMITACIONES:La naturaleza observacional del estudio podr&#xed;a considerarse una limitaci&#xf3;n.CONCLUSIONES:La escisi&#xf3;n abdominoperineal se asoci&#xf3; con dificultades para sentarse y caminar en pacientes con c&#xe1;ncer rectal con tasas significativamente mayores en comparaci&#xf3;n con la resecci&#xf3;n anterior. Es probable que la atenci&#xf3;n m&#xe9;dica pueda mejorar la situaci&#xf3;n de los pacientes mediante una mejor rehabilitaci&#xf3;n. (Traducci&#xf3;n-Dr Osvaldo Gauto ).</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Colon and Rectal Surgeons.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bj&#xf6;rklund Sand</LastName><ForeName>Lina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Surgery, SSORG-Scandinavian Surgical Outcomes Research Group, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Region V&#xe4;stra G&#xf6;taland, Alings&#xe5;s Lasarett, Alings&#xe5;s, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larsson</LastName><ForeName>Charlotta</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Surgery, SSORG-Scandinavian Surgical Outcomes Research Group, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Region V&#xe4;stra G&#xf6;taland, Sahlgrenska University Hospital/&#xd6;stra, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gr&#xf6;nkvist</LastName><ForeName>Rode</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Surgery, SSORG-Scandinavian Surgical Outcomes Research Group, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haglind</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Surgery, SSORG-Scandinavian Surgical Outcomes Research Group, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Region V&#xe4;stra G&#xf6;taland, Sahlgrenska University Hospital/&#xd6;stra, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angenete</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Surgery, SSORG-Scandinavian Surgical Outcomes Research Group, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Region V&#xe4;stra G&#xf6;taland, Sahlgrenska University Hospital/&#xd6;stra, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01477229</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="Y">Proctectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016138" MajorTopicYN="Y">Walking</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077708" MajorTopicYN="Y">Sitting Position</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010502" MajorTopicYN="N">Perineum</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abdominoperineal excision</Keyword><Keyword MajorTopicYN="N">Anterior resection</Keyword><Keyword MajorTopicYN="N">Perineal symptoms</Keyword><Keyword MajorTopicYN="N">Rectal cancer</Keyword><Keyword MajorTopicYN="N">Sitting difficulties</Keyword><Keyword MajorTopicYN="N">Walking difficulties</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>14</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>14</Day><Hour>11</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40085057</ArticleId><ArticleId IdType="pmc">PMC12094259</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003710</ArticleId><ArticleId IdType="pii">00003453-202506000-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Minsky BD. Emerging trends in the treatment of rectal cancer. Acta Oncol. 2019;58:1343&#x2013;1351.</Citation><ArticleIdList><ArticleId IdType="pubmed">31271081</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogner A, Kirchberg J, Weitz J, Fritzmann J. State of the art&#x2014;rectal cancer surgery. Visc Med. 2019;35:252&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6738181</ArticleId><ArticleId IdType="pubmed">31602388</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson AB, Venook AP, Al-Hawary MM, et al. . Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:1139&#x2013;1167.</Citation><ArticleIdList><ArticleId IdType="pubmed">36240850</ArticleId></ArticleIdList></Reference><Reference><Citation>West NP, Anderin C, Smith KJ, Holm T, Quirke P; European Extralevator Abdominoperineal Excision Study Group. Multicentre experience with extralevator abdominoperineal excision for low rectal cancer. Br J Surg. 2010;97:588&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pubmed">20186891</ArticleId></ArticleIdList></Reference><Reference><Citation>Asplund D, Haglind E, Angenete E. Outcome of extralevator abdominoperineal excision compared with standard surgery: results from a single centre. Colorectal Dis. 2012;14:1191&#x2013;1196.</Citation><ArticleIdList><ArticleId IdType="pubmed">22221401</ArticleId></ArticleIdList></Reference><Reference><Citation>Musters GD, Buskens CJ, Bemelman WA, Tanis PJ. Perineal wound healing after abdominoperineal resection for rectal cancer: a systematic review and meta-analysis. Dis Colon Rectum. 2014;57:1129&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pubmed">25101610</ArticleId></ArticleIdList></Reference><Reference><Citation>Colov EP, Klein M, Gogenur I. Wound complications and perineal pain after extralevator versus standard abdominoperineal excision: a nationwide study. Dis Colon Rectum. 2016;59:813&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">27505109</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakonarson A, Algethami N, Lydrup ML, Buchwald P. Perineal wound healing after abdominoperineal resection for rectal cancer: a retrospective cohort study. Int J Colorectal Dis. 2022;37:1029&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pubmed">35396618</ArticleId></ArticleIdList></Reference><Reference><Citation>Asplund D, Prytz M, Bock D, Haglind E, Angenete E. Persistent perineal morbidity is common following abdominoperineal excision for rectal cancer. Int J Colorectal Dis. 2015;30:1563&#x2013;1570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4624814</ArticleId><ArticleId IdType="pubmed">26245948</ArticleId></ArticleIdList></Reference><Reference><Citation>Feddern ML, Jensen TS, Laurberg S. Chronic pain in the pelvic area or lower extremities after rectal cancer treatment and its impact on quality of life: a population-based cross-sectional study. Pain. 2015;156:1765&#x2013;1771.</Citation><ArticleIdList><ArticleId IdType="pubmed">26010459</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiltink LM, Chen TY, Nout RA, et al. . Health-related quality of life 14 years after preoperative short-term radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomised trial. Eur J Cancer. 2014;50:2390&#x2013;2398.</Citation><ArticleIdList><ArticleId IdType="pubmed">25060825</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayers AE, Patel RK, Hunter IA. Perineal hernia formation following extralevator abdominoperineal excision. Colorectal Dis. 2015;17:351&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">25413255</ArticleId></ArticleIdList></Reference><Reference><Citation>Asplund D, Heath J, Gonzalez E, et al. . Self-reported quality of life and functional outcome in patients with rectal cancer&#x2014;QoLiRECT. Dan Med J. 2014;61:A4841.</Citation><ArticleIdList><ArticleId IdType="pubmed">24814743</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava GA, Tomba E, Sonino N. Clinimetrics: the science of clinical measurements. Int J Clin Pract. 2012;66:11&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">22171900</ArticleId></ArticleIdList></Reference><Reference><Citation>Ara T. Brunnermunzel.
https://cran.r-project.org/web/packages/brunnermunzel/brunnermunzel.pdf. Accessed December 21, 2024.</Citation></Reference><Reference><Citation>Mortensen AR, Thyo A, Emmertsen KJ, Laurberg S. Chronic pain after rectal cancer surgery&#x2014;development and validation of a scoring system. Colorectal Dis. 2019;21:90&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">30269401</ArticleId></ArticleIdList></Reference><Reference><Citation>Kvalitetsregister. Kunskapsbanken.
https://kunskapsbanken.cancercentrum.se/diagnoser/tjock-och-andtarmscancer/vardprogram/kvalitetsregister/. Accessed December 21, 2024.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38502565</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Low Rates of Colorectal Cancer Screening in First-Degree Relatives of Our Patients: Are We Failing Them?</ArticleTitle><Pagination><StartPage>903</StartPage><EndPage>910</EndPage><MedlinePgn>903-910</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003189</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Guidelines recommend screening those with a family history of early-onset colorectal cancer at age 40 years or 10 years before the age of their relative's diagnosis. Currently, there is no literature reporting the screening rate in these individuals, and no protocols are in place to identify and target this population for screening awareness.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to assess adherence to current screening guidelines among first-degree relatives of patients with early-onset colorectal cancer.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective and qualitative study involving a telephone survey where patients were asked about relative's screening status and barriers to screening.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Two community-based institutions between January 2018 and December 2021.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Individuals diagnosed with early-onset colorectal cancer who had undergone surgery at our institutions.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Rate of screening in first-degree relatives of our patients with early-onset colorectal cancer. Other factors measured included demographics, clinicopathologic characteristics, and screening barriers.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-six patients were identified. The survey response rate was 66.6% (n = 24). A total of 88 first-degree relatives who met the screening criteria resulted in 67.1% of patients (n = 59) having a known screening status. Of the 59 patients with known screening status, only 44% (n = 26) had undergone screening. Patients of Black race, having stage III/IV disease, having Medicare/Medicaid insurance, and living within Baltimore City County were more likely to have family members with unknown or no screening. Lack of insurance coverage was the most common barrier, which was noted in 12.5% of patients (n = 3), whereas 54.1% of patients (n = 13) reported no barriers to screening.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Retrospective design.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Most first-degree relatives of patients diagnosed with early-onset colorectal cancer do not undergo colorectal cancer screening. This could be attributed to the lack of protocols that could guarantee these individuals are informed of their elevated risk and the different options available for screening. Furthermore, our study suggests that racial and socioeconomic disparities exist among high-risk patients who should pursue screening. See Video Abstract .</AbstractText><AbstractText Label="BAJAS TASAS DE DETECCIN DEL CNCER COLORRECTAL EN LOS FAMILIARES DE PRIMER GRADO DE NUESTROS PACIENTES LES ESTAMOS FALLANDO" NlmCategory="UNASSIGNED">ANTECEDENTES:Las directrices recomiendan realizar pruebas de detecci&#xf3;n a las personas con antecedentes familiares de c&#xe1;ncer colorrectal de aparici&#xf3;n temprana a los 40 a&#xf1;os o 10 a&#xf1;os antes de la edad del diagn&#xf3;stico de su familiar. Actualmente, no hay literatura que informe la tasa de detecci&#xf3;n en estos individuos y no existen protocolos para identificar y dirigirse a esta poblaci&#xf3;n para concientizar sobre la detecci&#xf3;n.OBJETIVO:Evaluar el cumplimiento de las pautas de detecci&#xf3;n actuales entre los FDR de pacientes con c&#xe1;ncer colorrectal de aparici&#xf3;n temprana.DISE&#xd1;O:Estudio retrospectivo y cualitativo que incluy&#xf3; una encuesta telef&#xf3;nica en la que se pregunt&#xf3; a los pacientes sobre el estado de detecci&#xf3;n de sus familiares y las barreras para la detecci&#xf3;n.AJUSTES:Dos instituciones comunitarias entre enero de 2018 y diciembre de 2021.PACIENTES:Personas diagnosticadas con c&#xe1;ncer colorrectal de inicio temprano que hab&#xed;an sido intervenidas quir&#xfa;rgicamente en nuestras instituciones.PRINCIPALES MEDIDAS DE RESULTADO:Tasa de detecci&#xf3;n en familiares de primer grado de nuestros pacientes con c&#xe1;ncer colorrectal de aparici&#xf3;n temprana. Otros factores medidos incluyeron datos demogr&#xe1;ficos, caracter&#xed;sticas cl&#xed;nico-patol&#xf3;gicas y barreras de detecci&#xf3;n.RESULTADOS:Se identificaron treinta y seis pacientes. La tasa de respuesta a la encuesta fue del 66,6% (n = 24). Resultaron un total de 88 familiares de primer grado que cumplieron con los criterios para la detecci&#xf3;n, y el 67,1% (n = 59) ten&#xed;a un estado de detecci&#xf3;n conocido. De los 59 con estado de detecci&#xf3;n conocido, se inform&#xf3; que solo el 44% (n = 26) se hab&#xed;a sometido a pruebas de detecci&#xf3;n. Los pacientes de raza afroamericana, enfermedad en etapa III/IV, Medicare/Medicaid y que viv&#xed;an dentro del condado de la ciudad de Baltimore ten&#xed;an m&#xe1;s probabilidades de tener familiares con pruebas de detecci&#xf3;n desconocidas o sin ellas. La falta de cobertura de seguro fue la barrera m&#xe1;s com&#xfa;n observada por el 12,5% (n = 3); mientras que el 54,1% (n = 13) no inform&#xf3; ninguna barrera para el cribado.LIMITACIONES:Dise&#xf1;o retrospectivo.CONCLUSIONES:La mayor&#xed;a de los familiares de primer grado de pacientes diagnosticados con c&#xe1;ncer colorrectal de aparici&#xf3;n temprana no se someten a pruebas de detecci&#xf3;n de c&#xe1;ncer colorrectal. Esto podr&#xed;a atribuirse a la falta de protocolos que garanticen que estas personas est&#xe9;n informadas sobre su elevado riesgo y las diferentes opciones disponibles para el cribado. Adem&#xe1;s, nuestro estudio sugiere que existen disparidades raciales y socioecon&#xf3;micas entre los pacientes de alto riesgo que deber&#xed;an someterse a pruebas de detecci&#xf3;n. (Traducci&#xf3;n-Dr. Francisco M. Abarca-Rendon).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Almanzar</LastName><ForeName>Anyelin</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0003-5334-8270</Identifier><AffiliationInfo><Affiliation>Department of General Surgery, Medstar Franklin Square Medical Center, Rossville, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahmani</LastName><ForeName>Sophia L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>School of Medicine, Georgetown University, Washington, District of Columbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoucair</LastName><ForeName>Sami</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medstar Franklin Square Medical Center, Rossville, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alnajjar</LastName><ForeName>Said R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medstar Franklin Square Medical Center, Rossville, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Kan Hong</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medstar Franklin Square Medical Center, Rossville, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Vinay K</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medstar Franklin Square Medical Center, Rossville, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lisle</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medstar Franklin Square Medical Center, Rossville, Maryland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055088" MajorTopicYN="Y">Early Detection of Cancer</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019983" MajorTopicYN="N">Guideline Adherence</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036301" MajorTopicYN="N">Qualitative Research</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>13</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>19</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>19</Day><Hour>12</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38502565</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003189</ArticleId><ArticleId IdType="pii">00003453-202407000-00008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233&#x2013;254.</Citation></Reference><Reference><Citation>Venugopal A, Carethers JM. Epidemiology and biology of early onset colorectal cancer. EXCLI J. 2022;21:162&#x2013;182.</Citation></Reference><Reference><Citation>Lowery JT, Ahnen DJ, Schroy PC, et al. Understanding the contribution of family history to colorectal cancer risk and its clinical implications: a state-of-the-science review. Cancer. 2016;122:2633&#x2013;2645.</Citation></Reference><Reference><Citation>Schroy PC, Barrison AF, Ling BS, Wilson S, Geller AC. Family history and colorectal cancer screening: a survey of physician knowledge and practice patterns. Am J Gastroenterol. 2002;97:1031&#x2013;1036.</Citation></Reference><Reference><Citation>Center for Disease Control and Prevention. Family health history of colorectal (colon) cancer. https://www.cdc.gov/genomics/disease/colorectal_cancer/family_history_coloretal.htm . Published March 9, 2022. Accessed April 10, 2023.</Citation></Reference><Reference><Citation>Bronner K, Mesters I, Weiss-Meilnik A, et al. Do individuals with a family history of colorectal cancer adhere to medical recommendations for the prevention of colorectal cancer? Fam Cancer. 2013;12:629&#x2013;637.</Citation></Reference><Reference><Citation>Taylor DP, Cannon-Albright LA, Sweeney C, et al. Comparison of compliance for colorectal cancer screening and surveillance by colonoscopy based on risk. Genet Med. 2011;13:737&#x2013;743.</Citation></Reference><Reference><Citation>Lowery JT, Horick N, Kinney AY, et al. A randomized trial to increase colonoscopy screening in members of high-risk families in the colorectal cancer family registry and cancer genetics network. Cancer Epidemiol Biomarkers Prev. 2014;23:601&#x2013;610.</Citation></Reference><Reference><Citation>Bujanda L, Sarasqueta C, Zubiaurre L, et al.; EPICOLON Group. Low adherence to colonoscopy in the screening of first-degree relatives of patients with colorectal cancer. Gut. 2007;56:1714&#x2013;1718.</Citation></Reference><Reference><Citation>Courtney RJ, Paul CL, Carey ML, et al. A population-based cross-sectional study of colorectal cancer screening practices of first-degree relatives of colorectal cancer patients. BMC Cancer. 2013;13:13.</Citation></Reference><Reference><Citation>Tan KK, Lopez V, Wong ML, Koh GC. Uncovering the barriers to undergoing screening among first degree relatives of colorectal cancer patients: a review of qualitative literature. J Gastrointest Oncol. 2018;9:579&#x2013;588.</Citation></Reference><Reference><Citation>Sinicrope FA. Increasing incidence of early-onset colorectal cancer. N Engl J Med. 2022;386:1547&#x2013;1558.</Citation></Reference><Reference><Citation>Bailey CE, Hu C, You YN, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg. 2015;150:17&#x2013;22.</Citation></Reference><Reference><Citation>Stoffel EM, Murphy CC. Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults. Gastroenterology. 2020;158:341&#x2013;353.</Citation></Reference><Reference><Citation>Spaander MCW, Zauber AG, Syngal S, et al. Young-onset colorectal cancer. Nat Rev Dis Primers. 2023;9:21.</Citation></Reference><Reference><Citation>Muthukrishnan M, Arnold LD, James AS. Patients&#x2019; self-reported barriers to colon cancer screening in federally qualified health center settings. Prev Med Rep. 2019;15:100896.</Citation></Reference><Reference><Citation>Jackson CS, Oman M, Patel AM, Vega KJ. Health disparities in colorectal cancer among racial and ethnic minorities in the United States. J Gastrointest Oncol. 2016;7(suppl 1):S32&#x2013;S43.</Citation></Reference><Reference><Citation>Shah SK, Narcisse MR, Hallgren E, Felix HC, McElfish PA. Assessment of colorectal cancer screening disparities in us men and women using a demographically representative sample. Cancer Res Commun. 2022;2:561&#x2013;569.</Citation></Reference><Reference><Citation>Dougherty MK, Brenner AT, Crockett SD, et al. Evaluation of interventions intended to increase colorectal cancer screening rates in the United States: a systematic review and meta-analysis. JAMA Intern Med. 2018;178:1645&#x2013;1658.</Citation></Reference><Reference><Citation>Tai CH, Chen A, Khurana S, Mazurkiewicz R. Improving colorectal cancer screening compliance with resident education. Am J Gastroenterol. 2020;115:S1637&#x2013;S1638.</Citation></Reference><Reference><Citation>Parker S, Zipursky J, Ma H, Baumblatt GL, Siegel CA. A web-based multimedia program before colonoscopy increased knowledge and decreased anxiety, sedation requirement, and procedure time. J Clin Gastroenterol. 2018;52:519&#x2013;523.</Citation></Reference><Reference><Citation>Hart AR, Barone TL, Mayberry JF. Increasing compliance with colorectal cancer screening: the development of effective health education. Health Educ Res. 1997;12:171&#x2013;180.</Citation></Reference><Reference><Citation>Kew GS, Koh CJ. Strategies to improve persistent adherence in colorectal cancer screening. Gut Liver. 2020;14:546&#x2013;552.</Citation></Reference><Reference><Citation>Hassan C, Kaminski MF, Repici A. How to ensure patient adherence to colorectal cancer screening and surveillance in your practice. Gastroenterology. 2018;155:252&#x2013;257.</Citation></Reference><Reference><Citation>Uson PLS Jr, Riegert-Johnson D, Boardman L, et al. Germline cancer susceptibility gene testing in unselected patients with colorectal adenocarcinoma: a multicenter prospective study. Clin Gastroenterol Hepatol. 2022;20:e508&#x2013;e528.</Citation></Reference><Reference><Citation>Yurgelun MB, Kulke MH, Fuchs CS, et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol. 2017;35:1086&#x2013;1095.</Citation></Reference><Reference><Citation>You YN, Moskowitz JB, Chang GJ, et al. Germline cancer risk profiles of patients with young-onset colorectal cancer: findings from a prospective universal germline testing and telegenetics program. Dis Colon Rectum. 2023;66:531&#x2013;542.</Citation></Reference><Reference><Citation>Pearlman R, Frankel WL, Swanson B, et al.; Ohio Colorectal Cancer Prevention Initiative Study Group. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol. 2017;3:464&#x2013;471.</Citation></Reference><Reference><Citation>Pearlman R, Frankel WL, Swanson BJ, et al. Prospective statewide study of universal screening for hereditary colorectal cancer: the Ohio colorectal cancer prevention initiative. JCO Precis Oncol. 2021;5:779&#x2013;791.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38408874</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Hemorrhoidectomy: Does Age Make a Difference?</ArticleTitle><Pagination><StartPage>820</StartPage><EndPage>825</EndPage><MedlinePgn>820-825</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003085</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Grade II and III hemorrhoids often require a multimodal approach that may ultimately culminate in surgical resection. Age and overall medical conditioning around the time of diagnosis can often impact the decision.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this study was to evaluate patients with a diagnosis of symptomatic grade II or grade III hemorrhoids and determine progression to hemorrhoidectomy based on age and the time interval between diagnosis and surgical intervention.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A retrospective cohort study.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Group practice at a single institution.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients aged 18 to 75 years with grade II or grade III internal hemorrhoids between 2015 and 2020 were included. Patients with thrombosed hemorrhoids or surgical contraindications to hemorrhoidectomy were excluded. A total of 961 patients met inclusion criteria for grade II (n&#x2009;=&#x2009;442) and III (n&#x2009;=&#x2009;519) hemorrhoids.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Treatments included hemorrhoidectomy, in-office procedures, and/or medical management.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Baseline demographics, treatment choices, and time to hemorrhoidectomy (if applicable) were stratified and analyzed on the basis of hemorrhoid grade (grade II and III) and age groupings that were predetermined by the authors (18-30, 31-50, and 51-75 years).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with grade III versus grade II hemorrhoids were more likely to choose hemorrhoidectomy as the initial treatment management (27.6% vs 4.1%). Patients in the age groups of 18 to 30 and 30 to 50 years were more likely to choose hemorrhoidectomy as the initial treatment management compared to those in the age group of 51 to 75 years (23.5% and 22% vs 12.8%). In patients who were initially treated with medical management or office-based procedures and then progressed to hemorrhoidectomy, no significant differences in the length of time to hemorrhoidectomy were noted on the basis of hemorrhoid grade or age.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Data only looked at age groups and their treatment selection. Personal biases of surgeon and patient may alter results.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study shows that the younger population tends to seek hemorrhoidectomy first over the older population. See Video Abstract .</AbstractText><AbstractText Label="HEMORROIDECTOMA LA EDAD MARCA LA DIFERENCIA" NlmCategory="UNASSIGNED">ANTECEDENTES:Las hemorroides de grado II y III a menudo requieren un abordaje multimodal que en &#xfa;ltima instancia puede culminar en una resecci&#xf3;n quir&#xfa;rgica. La edad y el estado m&#xe9;dico general en el momento del diagn&#xf3;stico a menudo pueden afectar la decisi&#xf3;n.OBJETIVO:El objetivo de este estudio fue evaluar a pacientes con diagn&#xf3;stico de hemorroides sintom&#xe1;ticas grado II o grado III y determinar la progresi&#xf3;n a hemorroidectom&#xed;a en funci&#xf3;n de la edad y el intervalo de tiempo entre el diagn&#xf3;stico y la intervenci&#xf3;n quir&#xfa;rgica.DISE&#xd1;O:Estudio de cohorte retrospectivo.ESCENARIO:Pr&#xe1;ctica grupal en una sola instituci&#xf3;n.PACIENTES:Se incluy&#xf3; a pacientes de 18 a 75 a&#xf1;os con hemorroides internas de grado II o III entre 2015 y 2020. Se excluyeron los pacientes con hemorroides trombosadas o contraindicaciones quir&#xfa;rgicas para hemorroidectom&#xed;a. Un total de 961 pacientes cumplieron los criterios de inclusi&#xf3;n para hemorroides de Grado II (n=442) y III (n=519).INTERVENCI&#xd3;N:Los tratamientos incluyeron hemorroidectom&#xed;a, procedimientos en el consultorio y/o manejo m&#xe9;dico.PRINCIPALES MEDIDAS DE RESULTADO:Los datos demogr&#xe1;ficos iniciales, las opciones de tratamiento y el tiempo hasta la hemorroidectom&#xed;a (si corresponde) se estratificaron y analizaron seg&#xfa;n el grado de hemorroides (grado II y III) y los grupos de edad predeterminados por los autores (18-30, 31-50). y 51-75).RESULTADOS:Los pacientes con hemorroides de Grado III versus Grado II tuvieron m&#xe1;s probabilidades de elegir la hemorroidectom&#xed;a como tratamiento inicial (27,6% versus 4,1%). Los pacientes de los grupos de edad de 18 a 30 y de 30 a 50 a&#xf1;os ten&#xed;an m&#xe1;s probabilidades de elegir la hemorroidectom&#xed;a como tratamiento inicial en comparaci&#xf3;n con los de 51 a 75 a&#xf1;os (23,5% y 22% frente a 12,8%). En los pacientes que inicialmente fueron tratados con manejo m&#xe9;dico o procedimientos en el consultorio y luego progresaron a hemorroidectom&#xed;a, no se observaron diferencias significativas en el tiempo hasta la hemorroidectom&#xed;a seg&#xfa;n el grado o la edad de las hemorroides.LIMITACIONES:Los datos solo analizan los grupos de edad y su selecci&#xf3;n de tratamiento. Los sesgos personales del cirujano y del paciente pueden alterar los resultados.CONCLUSI&#xd3;N:Nuestro estudio muestra que la poblaci&#xf3;n m&#xe1;s joven tiende a buscar primero la hemorroidectom&#xed;a que la poblaci&#xf3;n de mayor edad. (Traducci&#xf3;n-Dr. Felipe Bellolio ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Capece</LastName><ForeName>Steven J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Lehigh Valley Health Network, Department of Surgery and Colorectal Surgery, Allentown, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Browning</LastName><ForeName>Charles J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Lehigh Valley Health Network, Department of Surgery and Colorectal Surgery, Allentown, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barros de Sousa</LastName><ForeName>Cesar A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Lehigh Valley Health Network, Department of Surgery and Colorectal Surgery, Allentown, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaak</LastName><ForeName>Kyle</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Lehigh Valley Health Network, Network Office of Research and Innovation, Allentown, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Justin Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Lehigh Valley Health Network, Department of Surgery and Colorectal Surgery, Allentown, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sangster</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Lehigh Valley Health Network, Department of Surgery and Colorectal Surgery, Allentown, Pennsylvania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006484" MajorTopicYN="Y">Hemorrhoids</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061865" MajorTopicYN="Y">Hemorrhoidectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061665" MajorTopicYN="N">Time-to-Treatment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>3</Day><Hour>18</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>26</Day><Hour>21</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38408874</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003085</ArticleId><ArticleId IdType="pii">00003453-202406000-00014</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Migaly J, Sun Z. Review of hemorrhoid disease: presentation and management. Clin Colon Rectal Surg. 2016;29:022&#x2013;029.</Citation></Reference><Reference><Citation>Lohsiriwat VH. from basic pathophysiology to clinical management. World J Gastroenterol. 2012;18:2009&#x2013;2017.</Citation></Reference><Reference><Citation>Cengiz T, Gorgun EH. A range of treatments. Cleve Clin J Med. 2019;86:612&#x2013;620.</Citation></Reference><Reference><Citation>De Marco S, Tiso D. Lifestyle and risk factors in hemorrhoidal disease. Front Surg. 2021;8:729166.</Citation></Reference><Reference><Citation>Iyer VS, Shrier I, Gordon PH. Long-term outcome of rubber band ligation for symptomatic primary and recurrent internal hemorrhoids. Dis Colon Rectum. 2004;47:1364&#x2013;1370.</Citation></Reference><Reference><Citation>Jutabha R, Jensen DM, Chavalitdhamrong D. Randomized prospective study of endoscopic rubber band ligation compared with bipolar coagulation for chronically bleeding internal hemorrhoids. Am J Gastroenterol. 2009;104:2057&#x2013;2064.</Citation></Reference><Reference><Citation>Salgueiro P, Caetano AC, Oliveira AM, et al. Portuguese Society of Gastroenterology consensus on the diagnosis and management of hemorrhoidal disease. GE Port J Gastroenterol. 2019;27:90&#x2013;102.</Citation></Reference><Reference><Citation>St-Louis E, Sudarshan M, Al-Habboubi M, et al. The outcomes of the elderly in acute care general surgery. Eur J Trauma Emerg Surg. 2015;42:107&#x2013;113.</Citation></Reference><Reference><Citation>Docimo S, Bates A, Alteri M, Talamini M, Pryor A, Spaniolas K. Evaluation of the use of component separation in elderly patients: results of a large cohort study with 30-day follow-up. Hernia. 2020;24:503&#x2013;507.</Citation></Reference><Reference><Citation>Yamamoto M, Ikeda M, Matsumoto T, et al. Hemorrhoidectomy for elderly patients aged 75 years or more, before and after studies. Ann Med Surg (Lond). 2020;55:88&#x2013;92.</Citation></Reference><Reference><Citation>Santos G, de A, Coutinho CP, Meyer MMMMDE, Sampaio DV, Cruz GMG. Surgical complications in 2,840 cases of hemorrhoidectomy by Milligan-Morgan, Ferguson and combined techniques. J Coloproctol (Rio J). 2012;32:271&#x2013;290.</Citation></Reference><Reference><Citation>Capece SJ, Browning CJ, Barros de Sousa C, Shaak K, Yoon J, Sangster W. Hemorrhoidectomy: does age make a difference? [ASCRS abstract eP425]. Dis Colon Rectum. 2023;66:e551.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38091488</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">0717-6384</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>07</Day></PubDate></JournalIssue><Title>Medwave</Title><ISOAbbreviation>Medwave</ISOAbbreviation></Journal><ArticleTitle>Community-acquired pneumonia: Epidemiology, diagnosis, prognostic severity scales, and new therapeutic options.</ArticleTitle><Pagination><StartPage>e2719</StartPage><MedlinePgn>e2719</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5867/medwave.2023.11.2719</ELocationID><Abstract><AbstractText>This narrative review article explores the current scientific knowledge on the definition, epidemiology, diagnostic criteria, microbiology, treatment, and prevention of severe community-acquired pneumonia (SCAP) in immunocompetent adults. At present, despite major scientific advances in diagnostic evaluation, clinical management, antimicrobial therapy, and prevention, severe community-acquired pneumonia remains a major cause of morbidity and mortality, as well as having a major economic impact in terms of increased healthcare expenditure worldwide. This pathology is considered one of the leading causes of sepsis/septic shock, with an extremely high overall mortality rate, which justifies all the effort in early diagnosis, proper management, and prompt initiation of antimicrobial therapy. Including biomarkers (isolated or in combination) associated with applying diagnostic criteria and prognostic severity scales in clinical practice helps identify patients with severe community-acquired pneumonia, defines immediate admission to the intensive care unit, and, thus, minimizes the adverse outcomes of this serious pathology.</AbstractText><CopyrightInformation>This work is licensed under a Creative Commons Attribution 4.0 International License.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oliveira E Silva</LastName><ForeName>Paulo Guilherme</ForeName><Initials>PG</Initials><Identifier Source="ORCID">0009-0002-4903-1724</Identifier><AffiliationInfo><Affiliation>Research Department, Imed Group Brasil, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cerqueira Batista Filho</LastName><ForeName>Luiz Alberto</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0002-8510-2115</Identifier><AffiliationInfo><Affiliation>Research Department, Imed Group Brasil, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ismael</LastName><ForeName>P&#xe9;rez Flores</ForeName><Initials>PF</Initials><Identifier Source="ORCID">0009-0000-0462-4978</Identifier><AffiliationInfo><Affiliation>Research Department, Imed Group Brasil, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Victoria</LastName><ForeName>Vilins E Silva</ForeName><Initials>VES</Initials><Identifier Source="ORCID">0009-0000-4301-8807</Identifier><AffiliationInfo><Affiliation>Research Department, Imed Group Brasil, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexandre</LastName><ForeName>Toledo Maciel</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0001-6043-0967</Identifier><AffiliationInfo><Affiliation>Research Department, Imed Group Brasil, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larissa</LastName><ForeName>Seraphim Medeiros</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0001-9522-8566</Identifier><AffiliationInfo><Affiliation>Research Department, Imed Group Brasil, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Neumon&#xed;a adquirida en la comunidad: epidemiolog&#xed;a, diagn&#xf3;stico, escalas pron&#xf3;sticas de gravedad y nuevas opciones terap&#xe9;uticas.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Chile</Country><MedlineTA>Medwave</MedlineTA><NlmUniqueID>101581949</NlmUniqueID><ISSNLinking>0717-6384</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011014" MajorTopicYN="Y">Pneumonia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017714" MajorTopicYN="Y">Community-Acquired Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000890" MajorTopicYN="Y">Anti-Infective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Este art&#xed;culo de revisi&#xf3;n narrativa tiene como objetivo explorar el conocimiento actual disponible basado en datos cient&#xed;ficos respeto a la definici&#xf3;n, la epidemiolog&#xed;a, los criterios diagn&#xf3;sticos, la microbiolog&#xed;a, el tratamiento y la prevenci&#xf3;n de la neumon&#xed;a grave adquirida en la comunidad) en individuos adultos inmunocompetentes. En la actualidad, pese a los grandes avances cient&#xed;ficos obtenidos en la evaluaci&#xf3;n diagn&#xf3;stica, el manejo cl&#xed;nico, la terapia antimicrobiana y la prevenci&#xf3;n, la neumon&#xed;a grave adquirida en la comunidad sigue siendo una causa importante de morbilidad y mortalidad, adem&#xe1;s de producir un gran impacto econ&#xf3;mico con la elevaci&#xf3;n de los costes sanitarios en todo el mundo. Esta patolog&#xed;a es considerada una de las principales causas de sepsis/choque s&#xe9;ptico, con una tasa de mortalidad global extremadamente elevada, lo que justifica todo el esfuerzo en el diagn&#xf3;stico precoz, el manejo en un ambiente adecuado y el inicio temprano y apropiado de la terapia antimicrobiana. La inclusi&#xf3;n de biomarcadores (aislados o en combinaci&#xf3;n) asociada a la aplicaci&#xf3;n de los criterios diagn&#xf3;sticos y escalas pron&#xf3;sticas de gravedad en la pr&#xe1;ctica cl&#xed;nica, sirven para identificar a los pacientes con neumon&#xed;a adquirida en la comunidad grave, definir el ingreso inmediato en la unidad de cuidados intensivos y, de esta forma, minimizar los resultados negativos de esta grave patolog&#xed;a.</AbstractText><CopyrightInformation>This work is licensed under a Creative Commons Attribution 4.0 International License.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Pneumonia</Keyword><Keyword MajorTopicYN="N">adult</Keyword><Keyword MajorTopicYN="N">hospital mortality</Keyword><Keyword MajorTopicYN="N">intensive care</Keyword><Keyword MajorTopicYN="N">intensive therapy</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>14</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38091488</ArticleId><ArticleId IdType="doi">10.5867/medwave.2023.11.2719</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35239524</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Prognostic Factors of Bone Metastases From Colorectal Cancer in the Era of Targeted Therapy.</ArticleTitle><Pagination><StartPage>401</StartPage><EndPage>409</EndPage><MedlinePgn>401-409</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002270</ELocationID><Abstract><AbstractText Label="BACKGROUND">Various prognostic factors have been reported for bone metastases from different primary tumor sites. However, bone metastases from colorectal cancer are very rare, and the prognostic factors have not been investigated in detail.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to identify prognostic factors of bone metastases from colorectal cancer.</AbstractText><AbstractText Label="DESIGN">This is a retrospective cohort study using data from a prospectively collected database.</AbstractText><AbstractText Label="SETTINGS">This study was conducted at a single tertiary care cancer center in Japan.</AbstractText><AbstractText Label="PATIENTS">Patients who developed bone metastases from colorectal cancer during the study period among all patients who received initial treatment for colorectal cancer at our hospital between 2005 and 2016 (n = 4538) were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Overall survival after diagnosis of bone metastases from colorectal cancer was the main outcome measure.</AbstractText><AbstractText Label="RESULTS">Ninety-four patients developed bone metastases during the study period. The 5-year overall survival rate was 11.0%. Multivariable analysis identified the following independent risk factors associated with poor prognosis: &#x2265;70 years of age at diagnosis of bone metastases (HR, 2.48; 95% CI, 1.24-4.95; p &lt; 0.01), curative surgery not performed as initial treatment (HR, 2.54; 95% CI, 1.24-5.19; p = 0.01), multiple bone metastases (HR, 2.44; 95% CI, 1.30-4.57; p &lt; 0.01), albumin level &lt;3.7&#x2009;g/dL (HR, 3.80; 95% CI, 1.95-7.39; p &lt; 0.01), CEA &#x2265;30&#x2009;ng/mL (HR, 1.94; 95% CI, 1.09-3.46; p = 0.02), and less than 3 chemotherapy options remaining at diagnosis of bone metastases (HR, 2.83; 95% CI, 1.51-5.30; p &lt; 0.01). The median survival times for patients with 0-2, 3, and 4-6 risk factors were 25.0, 8.8, and 4.3 months, respectively.</AbstractText><AbstractText Label="LIMITATIONS">The main limitation is the single-center, retrospective design of this study.</AbstractText><AbstractText Label="CONCLUSIONS">Our results may facilitate multidisciplinary decision-making in patients with bone metastases from colorectal cancer. See Video Abstract at http://links.lww.com/DCR/B930 .</AbstractText><AbstractText Label="FACTORES PRONSTICOS DE LAS METSTASIS SEAS DEL CNCER COLORRECTAL EN LA ERA DE LA TERAPIA DIRIGIDA">ANTECEDENTES:Se han reportado varios factores pron&#xf3;sticos para las met&#xe1;stasis &#xf3;seas de diferentes sitios de tumores primarios. Sin embargo, las met&#xe1;stasis &#xf3;seas del c&#xe1;ncer colorrectal son muy raras y los factores pron&#xf3;sticos no se han investigado en detalle.OBJETIVO:Identificar los factores pron&#xf3;sticos de las met&#xe1;stasis &#xf3;seas del c&#xe1;ncer colorrectal.DISE&#xd1;O:Estudio de cohorte retrospectivo utilizando datos de una base de datos recolectada prospectivamente.ENTORNO CLINICO:Un solo centro oncol&#xf3;gico de atenci&#xf3;n terciaria en Jap&#xf3;n.PACIENTES:Se seleccionaron pacientes que desarrollaron met&#xe1;stasis &#xf3;seas de c&#xe1;ncer colorrectal durante el per&#xed;odo de estudio entre todos los pacientes que recibieron tratamiento inicial para el c&#xe1;ncer colorrectal en nuestro hospital entre 2005 y 2016 (n = 4538).MEDIDA DE RESULTADO PRINCIPAL:Supervivencia general despu&#xe9;s del diagn&#xf3;stico de met&#xe1;stasis &#xf3;seas por c&#xe1;ncer colorrectal.RESULTADOS:Noventa y cuatro pacientes desarrollaron met&#xe1;stasis &#xf3;seas, lo que representa el 2,0% de todos los pacientes con c&#xe1;ncer colorrectal que comenzaron el tratamiento durante el per&#xed;odo de estudio. La tasa de supervivencia global a 5 a&#xf1;os fue del 11,0 %. El an&#xe1;lisis multivariable identific&#xf3; los siguientes factores de riesgo independientes asociados con mal pron&#xf3;stico: edad &#x2265;70 a&#xf1;os al momento del diagn&#xf3;stico de met&#xe1;stasis &#xf3;seas (hazard ratio 2,48, CI del 95 % 1,24-4,95, p &lt; 0,01), cirug&#xed;a curativa no realizada como tratamiento inicial (hazard ratio 2,54, CI 95 % 1,24-5,19, p = 0,01), met&#xe1;stasis &#xf3;seas m&#xfa;ltiples (hazard ratio 2,44, CI del 95 % 1,30-4,57, p &lt; 0,01), nivel de alb&#xfa;mina &lt;3,7 g/dL (hazard ratio 3,80, CI del 95 % 1,95 -7,39, p &lt; 0,01), ant&#xed;geno carcinoembrionario &#x2265;30 ng/mL (hazard ratio 1,94, CI del 95 % 1,09-3,46, p = 0,02) y menos de 3 opciones de quimioterapia restantes al momento del diagn&#xf3;stico de met&#xe1;stasis &#xf3;seas (hazard ratio 2,83, 95 % CI 1,51-5,30, p &lt; 0,01). La mediana de los tiempos de supervivencia para los pacientes con 0-2, 3 y 4-6 factores de riesgo fue de 25,0, 8,8 y 4,3 meses, respectivamente.LIMITACIONES:Dise&#xf1;o retrospectivo de un solo centro.CONCLUSI&#xd3;N:Nuestros resultados pueden facilitar la toma de decisiones multidisciplinares en pacientes con met&#xe1;stasis &#xf3;seas de c&#xe1;ncer colorrectal. Consulte Video Resumen en http://links.lww.com/DCR/B930 . (Traducci&#xf3;n- Dr. Francisco M. Abarca-Rendon ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Yasunobu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shida</LastName><ForeName>Dai</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Frontier Surgery, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boku</LastName><ForeName>Narikazu</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasui</LastName><ForeName>Kohei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Yuya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kudose</LastName><ForeName>Yozo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imaizumi</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanemitsu</LastName><ForeName>Yukihide</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>3</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35239524</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002270</ArticleId><ArticleId IdType="pii">00003453-202303000-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394&#x2013;424.</Citation></Reference><Reference><Citation>Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383:1490&#x2013;1502.</Citation></Reference><Reference><Citation>Zhenghong, Zhu Z, Guoweijian, . Retrospective study of predictors of bone metastasis in colorectal cancer patients. J Bone Oncol. 2017;9:25&#x2013;28.</Citation></Reference><Reference><Citation>Roth ES, Fetzer DT, Barron BJ, Joseph UA, Gayed IW, Wan DQ. Does colon cancer ever metastasize to bone first? A temporal analysis of colorectal cancer progression. BMC Cancer. 2009;9:274.</Citation></Reference><Reference><Citation>Sun C, Deng Y, Zhou H, Hu ZQ. Risk factors for the development of metachronous bone metastasis in colorectal cancer patients after curative resection. Int J Surg. 2015;21:145&#x2013;149.</Citation></Reference><Reference><Citation>Kawamura H, Yamaguchi T, Yano Y, et al. Characteristics and prognostic factors of bone metastasis in patients with colorectal cancer. Dis Colon Rectum. 2018;61:673&#x2013;678.</Citation></Reference><Reference><Citation>Zhang L, Gong Z. Clinical characteristics and prognostic factors in bone metastases from lung cancer. Med Sci Monit. 2017;23:4087&#x2013;4094.</Citation></Reference><Reference><Citation>Chen S, Wang L, Qian K, et al. Establishing a prediction model for prostate cancer bone metastasis. Int J Biol Sci. 2019;15:208&#x2013;220.</Citation></Reference><Reference><Citation>Kanthan R, Loewy J, Kanthan SC. Skeletal metastases in colorectal carcinomas: a Saskatchewan profile. Dis Colon Rectum. 1999;42:1592&#x2013;1597.</Citation></Reference><Reference><Citation>Yazdani A, Dorri S, Atashi A, Shirafkan H, Zabolinezhad H. Bone metastasis prognostic factors in breast cancer. Breast Cancer (Auckl). 2019;13:1178223419830978.</Citation></Reference><Reference><Citation>Choi SJ, Kim JH, Lee MR, Lee CH, Kuh JH, Kim JR. Long-term disease-free survival after surgical resection for multiple bone metastases from rectal cancer. World J Clin Oncol. 2011;2:326&#x2013;328.</Citation></Reference><Reference><Citation>Santini D, Tampellini M, Vincenzi B, et al. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol. 2012;23:2072&#x2013;2077.</Citation></Reference><Reference><Citation>Li A, K&#xe4;smann L, Rades D, Fu C. A scoring system to predict the development of bone metastasis after radical resection of colorectal cancer. Anticancer Res. 2017;37:5169&#x2013;5172.</Citation></Reference><Reference><Citation>Tokuhashi Y, Uei H, Oshima M, Ajiro Y. Scoring system for prediction of metastatic spine tumor prognosis. World J Orthop. 2014;5:262&#x2013;271.</Citation></Reference><Reference><Citation>Katagiri H, Okada R, Takagi T, et al. New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med. 2014;3:1359&#x2013;1367.</Citation></Reference><Reference><Citation>Baek SJ, Hur H, Min BS, Baik SH, Lee KY, Kim NK. The characteristics of bone metastasis in patients with colorectal cancer: a long-term report from a single institution. World J Surg. 2016;40:982&#x2013;986.</Citation></Reference><Reference><Citation>Shida D, Tanabe T, Boku N, et al. Prognostic value of primary tumor sidedness for unresectable stage IV colorectal cancer: a retrospective study. Ann Surg Oncol. 2019;26:1358&#x2013;1365.</Citation></Reference><Reference><Citation>Shida D, Boku N, Tanabe T, et al. Primary tumor resection for stage IV colorectal cancer in the era of targeted chemotherapy. J Gastrointest Surg. 2019;23:2144&#x2013;2150.</Citation></Reference><Reference><Citation>Paulino Pereira NR, Mclaughlin L, Janssen SJ, et al. The SORG nomogram accurately predicts 3- and 12-months survival for operable spine metastatic disease: external validation. J Surg Oncol. 2017;115:1019&#x2013;1027.</Citation></Reference><Reference><Citation>Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209&#x2013;1214.</Citation></Reference><Reference><Citation>Jung M, Ahn JB, Chang JH, et al. Brain metastases from colorectal carcinoma: prognostic factors and outcome. J Neurooncol. 2011;101:49&#x2013;55.</Citation></Reference><Reference><Citation>Imaizumi J, Shida D, Narita Y, et al. Prognostic factors of brain metastases from colorectal cancer. BMC Cancer. 2019;19:755.</Citation></Reference><Reference><Citation>Ghori AK, Leonard DA, Schoenfeld AJ, et al. Modeling 1-year survival after surgery on the metastatic spine. Spine J. 2015;15:2345&#x2013;2350.</Citation></Reference><Reference><Citation>Ghuman S, Van Hemelrijck M, Garmo H, et al. Serum inflammatory markers and colorectal cancer risk and survival. Br J Cancer. 2017;116:1358&#x2013;1365.</Citation></Reference><Reference><Citation>Wang F, Li P, Li FS. Prognostic role of C-reactive protein to albumin ratio in colorectal cancer: a meta analysis. Medicine (Baltimore). 2019;98:e16064.</Citation></Reference><Reference><Citation>Wei Y, Xu H, Dai J, et al. Prognostic significance of serum lactic acid, lactate dehydrogenase, and albumin levels in patients with metastatic colorectal cancer. Biomed Res Int. 2018;2018:1804086.</Citation></Reference><Reference><Citation>Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69.</Citation></Reference><Reference><Citation>McMillan DC, Watson WS, O&#x2019;Gorman P, Preston T, Scott HR, McArdle CS. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer. 2001;39:210&#x2013;213.</Citation></Reference><Reference><Citation>Dotan E, Tew WP, Mohile SG, et al. Associations between nutritional factors and chemotherapy toxicity in older adults with solid tumors. Cancer. 2020;126:1708&#x2013;1716.</Citation></Reference><Reference><Citation>Song M, Chan AT. The potential role of exercise and nutrition in harnessing the immune system to improve colorectal cancer survival. Gastroenterology. 2018;155:596&#x2013;600.</Citation></Reference><Reference><Citation>Bates T. A review of local radiotherapy in the treatment of bone metastases and cord compression. Int J Radiat Oncol Biol Phys. 1992;23:217&#x2013;221.</Citation></Reference><Reference><Citation>Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol. 1991;9:509&#x2013;524.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>